Table 1.
Patient characteristics and corresponding pCR rates
| All patients | QpCR | CpCR | CpCRbn | SpCR | SpCRbn | p value | |||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| All patients | 353 (100) | 98 (27.8 %) | 72 (20.4) | 65 (18.4) | 35 (9.9 %) | 29 (8.2 %) | |||||
| Study | |||||||||||
| JBCRG-01 | 186 (52.7) | 47 (25.3) | p = 0.43 | 31 (16.7) | p = 0.13 | 29 (15.6) | p = 0.32 | 15 (8.1) | p = 0.32 | 14 (7.5) | p = 0.81 |
| JBCRG-02 | 37 (10.5) | 13 (35.1) | 11 (29.7) | 9 (24.3) | 6 (16.2) | 4 (10.8) | |||||
| JBCRG-03 | 130 (36.8) | 38 (29.3) | 30 (23.1) | 27 (20.8) | 14 (10.8) | 11 (8.5) | |||||
| Age | |||||||||||
| <50 | 231 (65.4) | 61 (26.4) | p = 0.44 | 45 (19.5) | p = 0.56 | 39 (16.9) | p = 0.31 | 26 (11.3) | p = 0.24 | 21 (9.1) | p = 0.40 |
| ≥50 | 122 (34.6) | 37 (30.3) | 27 (22.1) | 26 (21.3) | 9 (7.4) | 8 (6.6) | |||||
| Tumor | |||||||||||
| ≤3 cm | 207 (58.6) | 55 (26.6) | p = 0.56 | 42 (20.3) | p = 0.95 | 36 (17.4) | p = 0.56 | 20 (9.7) | p = 0.85 | 15 (7.3) | p = 0.43 |
| >3 cm | 146 (41.4) | 43 (29.5) | 30 (20.6) | 29 (19.9) | 15 (10.3) | 14 (9.6) | |||||
| Nuclear grade | |||||||||||
| Grade 1 | 69 (19.6) | 11 (15.9) | p = 0.036 | 5 (7.3) | p = 0.004 | 5 (7.3) | p = 0.009 | 2 (2.9) | p = 0.011 | 2 (2.9) | p = 0.016 |
| Grade 2 | 102 (28.9) | 31 (30.4) | 24 (23.5) | 21 (20.6) | 9 (8.8) | 7 (6.9) | |||||
| Grade 3 | 76 (21.5) | 25 (32.9) | 20 (26.3) | 19 (25.0) | 13 (17.1) | 12 (15.8) | |||||
| Unknown | 106 (30.0) | ||||||||||
| Nodal status | |||||||||||
| n0 | 143 (40.5) | 83 (39.5) | p < 0.001 | 65 (31.0) | p < 0.001 | 65 (31.0) | p < 0.001 | 29 (13.8) | p = 0.002 | 29 (13.8) | p < 0.001 |
| n+ | 210 (59.5) | 15 (10.5) | 7 (4.9) | 0 (0.0) | 6 (4.2) | 0 (0.0) | |||||
| Subtype | |||||||||||
| Luminal | 206 (58.4) | 32 (15.5) | p < 0.001 | 19 (9.2) | p < 0.001 | 18 (8.7) | p < 0.001 | 6 (2.9) | p < 0.001 | 5 (2.4) | p < 0.001 |
| Luminal/Her2-positive | 34 (9.6) | 14 (41.2) | 8 (23.5) | 7 (20.6) | 5 (14.7) | 4 (11.8) | |||||
| Her2-positive | 40 (11.3) | 21 (52.5) | 17 (42.5) | 15 (37.5) | 6 (15.0) | 5 (12.5) | |||||
| Triple negative | 73 (20.7) | 31 (42.5) | 28 (38.4) | 25 (34.3) | 18 (24.7) | 15 (20.6) | |||||
| Clinical response after the first half of NAC | |||||||||||
| CR, PR | 214 (60.6) | 69 (32.2) | p = 0.018 | 51 (23.8) | p = 0.044 | 47 (22.0) | p = 0.030 | 27 (12.6) | p = 0.029 | 23 (10.8) | p = 0.025 |
| SD, PD | 139 (39.4) | 29 (20.9) | 21 (15.1) | 18 (13.0) | 8 (5.8) | 6 (4.3) | |||||
| Clinical response before surgery | |||||||||||
| CR, PR | 261 (74.0) | 82 (31.4) | p = 0.06 | 62 (23.8) | p = 0.003 | 56 (21.5) | p = 0.005 | 31 (11.9) | p = 0.031 | 26 (10.0) | p = 0.034 |
| SD, PD | 89 (25.2) | 15 (16.9) | 9 (10.1) | 8 (9.0) | 4 (4.5) | 3 (3.4) | |||||
| Unknown | 3 (0.8) | ||||||||||
CR complete response, NAC neoadjuvant chemotherapy, n+ node positive, PR partial response, SD stable disease, PD progressive disease